<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108234</url>
  </required_header>
  <id_info>
    <org_study_id>HR071603-101</org_study_id>
    <nct_id>NCT04108234</nct_id>
  </id_info>
  <brief_title>A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects</brief_title>
  <official_title>Safety, Tolerance and Pharmacokinetics of Hydrochloric Acid (R) -Ketamine Nasal Spray in Healthy Subjects: A Randomized, Double Blind, Placebo-Controlled Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety and pharmacokinetics of HR071603 in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HR071603 monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Pre-dose to Day8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-Area under drug-time curve (AUC)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-peak time (Tmax)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-peak concentration (Cmax)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-half-life (t1/2)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-apparent clearance rate (CL/F)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-apparent distribution volume (Vz/F)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR071603,nasal spray,dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR071603</intervention_name>
    <description>HR071603 monotherapy ,nasal spray</description>
    <arm_group_label>Treatment group A</arm_group_label>
    <other_name>R-ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo,nasal spray</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obtain informed consent prior to the start of any activity related to the trial, and
             have a thorough understanding of the purpose and meaning of the trial and be willing
             to comply with the protocol;

          2. Healthy males aged between 18 and 45 (including both ends);

          3. Weight ≥ 50kg, body mass index (BMI) in the range of 18.5 ~ 23.9 (including both
             ends);

          4. During the trial and within 30 days after the administration, willing to take
             contraceptive measures and ensure that no sperm is donated.

        Exclusion Criteria:

          1. A subject considered by the investigator to be unsuitable for nasal spray
             administration;

          2. Allergic to any component of the study drug;

          3. The underlying disease is not suitable for participation in the trial;

          4. 12-lead ECG results in the screening period are abnormal and clinically significant

          5. Liver dysfunction;

          6. Serum creatinine &gt; 1.2 × ULN during screening period;

          7. Screening for infectious diseases screening hepatitis B surface antigen (HBsAg),
             hepatitis C antibody (HCVAb), syphilis antibody, human immunodeficiency virus (HIV)
             antibody test positive;

          8. Subject has been thoroughly examined, and the results are abnormal and clinically
             significant;

          9. Major operations were performed within 3 months before the screening period.

         10. Donate whole blood/plasma within one month before the screening period, or donate
             whole blood/plasma more than 400 ml within three months before the screening period;

         11. Positive urine drug test;

         12. The alcohol breath test is positive; or the average daily intake of alcohol exceeds
             15g;

         13. Nicotine test is positive;

         14. History of drug abuse or alcohol abuse;

         15. In the past three months, over five cups of coffee or tea per day were consumed in an
             average;

         16. Any prescription drugs, over-the-counter drugs and health products were used within 2
             weeks before screening.

         17. Participated in clinical trials of any drug or medical device within 3 months before
             screening ;

         18. Any other medical or psychological condition, which in the opinion of the
             Investigator, might create undue risk to the participant or interfere with the
             participant's ability to comply with the protocol requirements, or to complete the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianjun Zou</last_name>
    <phone>021-68868570</phone>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiaoli cai</last_name>
    <phone>02161623506</phone>
    <email>caixiaoli@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing AnDing hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanyue Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

